Clinical trial finds J&J’s tapentadol ER reduces lower back pain in patients
RARITAN, N.J. An investigational drug made by Johnson & Johnson for treating pain showed significant reduction in pain intensity compared with placebo in patients with moderate to severe lower back pain, according to results of a late-stage clinical trial announced Monday.
Results of a phase-3 trial, published online in the journal Expert Opinion on Pharmacotherapy, indicated that tepentadol extended-release tablets reduced pain by at least 30% in patients compared with placebo. The drug uses the same active ingredient as J&J’s Nucynta, an immediate-release formulation.
“The study provides important data regarding the safety and efficacy of tapentadol ER,” said Bruce Moskovitz, therapeutic area leader for pain at Ortho-McNeil-Janssen Scientific Affairs, a division of J&J. “We are pleased that results show tapentadol ER may effectively relieve moderate to severe chronic low back pain while demonstrating a favorable tolerability profile.”
Pfizer recalls lot of ThermaCare HeatWraps Menstrual
NEW YORK Pfizer’s over-the-counter division recalled one lot of a ThermaCare product over the possibility of leaks.
Pfizer Consumer Healthcare announced Friday the voluntary recall of lot number E06931 of its ThermaCare HeatWraps Menstrual product and notified the Food and Drug Administration.
The company said possible leaks in the wraps could cause skin injury, such as irritation and burning.
Tenn.-based pharmacy acquired by Capital Group Holdings
SCOTTSDALE, Ariz. Capital Group Holdings has acquired Main Street Family Pharmacy in Newbern, Tenn., Capital Group said Friday.
Main Street Family Pharmacy provides retail prescriptions, compounding, durable medical equipment and home infusion services, as well as disposable medical office supplies. The pharmacy also specializes in comprehending compounding services, providing products for hormone-replacement therapy, dermatology and other areas.
“The acquisition of Main Street Family Pharmacy provides us with a strong foundation in the health-and-wellness market and will enable us to pursue additional strategic opportunities,” Capital Group Holdings CEO Christopher Galvin said.